FOLH1 and prostate cancer: In the primary setting, the proPSMA trial demonstrated a higher diagnostic accuracy of PSMA PET-CT compared to conventional imaging in high-risk patients with prostate cancer and suggested using PSMA PET-CT for staging in high-risk primary prostate cancer [22].